Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2003

View Archived Issues

Tricyclic angiotensin AT2 agonists recently identified at Vicore

Miravant claims metalloporphyrin photosensitizers for cardiovascular PDT

Novel HIV protease inhibitors in early development at Merck

Novartis researchers describe novel proteasome inhibitors

Cytokine production inhibitors newly developed at Boehringer Ingelheim

Schering scientists present CDK and GSK-3 inhibitors for cancer and other uses

Wyeth develops novel modulators of 5-HT transporter

New antibacterial DNA gyrase inhibitors prepared and tested at Pfizer

Antiapoptotic fusion protein protects against ischemic brain injury

Blockade of myostatin leads to improvement in muscle function in dystrophic mice

AT-3639: new quinolone with antitumor activity generally comparable to etoposide

Velcade enters phase II trial in NSCLC

Ranbezolid development advances on two fronts

Potential of angiotensin receptor blocker in diabetic nephropathy

DN-101 evaluated in phase II trial in myelodysplastic syndromes

StressGen's HspE7 studied in NCI-sponsored trials for HPV-related diseases

Shire licenses Solaraze rights in Australia and certain Pacific Rim territories

Xenova buys out ImmuLogic's interests in TA-CD and TA-NIC programs

Enrollment complete in phase I/II trial of TheraCIM h-R3 in head and neck cancer

YM BioSciences' prostate cancer vaccine trial completes enrollment

Abbott to use Compugen technology to identify and prioritize new drug targets

Bolder receives grant to develop TPO proteins for thrombocytopenia

Antiarthritic effects demonstrated for a selective CXCR2 antagonist

Bioxel enters R&D collaboration for paclitaxel derivatives

Incara and Elan terminate option agreement for catalytic antioxidants

Neurion and Pfizer to model drug interactions with HERG ion channel

Structural GenomiX and Boehringer Ingelheim form collaboration

AstraZeneca's Oxis Turbuhaler completes mutual recognition procedure for COPD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...